Latest in News & Research
Predictive Model Shows Moderate Performance for Psoriasis Relapse Risk
BMI, diabetes, biologic use, smoking, URTI, nonstandard medication were identified as independent risk factors and included in model
Atopic Dermatitis Linked to Sleep, Memory Disturbances
Higher risk seen with increasing disease severity
Machine Learning Predicts Asthma Risk in Children With Early-Life Atopic Dermatitis
Models built based on routine electronic health record data
The Long View of Atopic Dermatitis Control
In treating atopic dermatitis, the question is not only how quickly a patient can improve, but how to build a plan that respects the...
News Alert: Phase 3 ONWARD Trials Evaluate Envudeucitinib in Moderate to Severe Plaque Psoriasis
Findings presented at AAD26 highlight rapid onset and deepening responses through week 24
A Shift in Access for Actinic Keratosis
A late-March formulary update may change how often tirbanibulin is a realistic option in clinic.
Maternal Prepregnancy BMI, Birth Length Linked to Offspring Atopic Dermatitis
Increasing birth length positively associated with atopic dermatitis by age 3 years, while inverse association seen for short birth length
American Academy of Dermatology, March 27 to 31
The annual meeting of the American Academy of Dermatology was held from March 27 to 31 in Denver and attracted clinicians, academicians, allied health...
Recommendations Developed for Prevention of Pediatric Atopic Dermatitis
Guidelines also developed for medical management of pediatric atopic dermatitis, including 27 evidence-based recommendations
Mortality Varies With Primary Tumor Location in Cutaneous Melanoma
Increased mortality seen with primary tumor location in head and neck site; mortality reduced for location in upper limb/shoulder and lower limb/hip
Consensus-Based Definitions Developed for Disease Activity in Atopic Dermatitis
Definitions developed for low disease activity, very low disease activity, remission in atopic dermatitis
News Alert: Deucravacitinib Approved for Psoriatic Arthritis
An oral TYK2 inhibitor now carries an indication across both skin and joint disease
What It Means to Treat Something That Doesn’t Behave Consistently
Atopic dermatitis rarely behaves the same way twice, which means the real work of treating it begins in everything we don’t immediately see.
International Severity Criteria Developed for Vitiligo
Major criteria for vitiligo include spread or active disease, involvement of highly visible or high-impact areas, psychological distress
AAD: Zasocitinib Safe, Effective for Moderate-to-Severe Plaque Psoriasis in Adults
Phase 3 studies show the highly selective oral tyrosine kinase 2 inhibitor provides rapid, durable skin improvement
AAD: Upadacitinib Safe, Effective for Nonsegmental Vitiligo
Benefits include total and facial repigmentation in patients 12 years and older versus placebo
AAD: Ixekizumab + Tirzepatide Boosts Psoriatic Arthritis Outcomes More Than Ixekizumab Monotherapy
Ixekizumab plus tirzepatide tied to simultaneous benefit of American College of Rheumatology 50 percent improvement and weight reduction
AAD: Subcutaneous Amlitelimab Aids Atopic Dermatitis Outcomes Through Week 24
Findings seen for skin clearance and disease severity with both every-four-week and every-12-week dosing
Topical Melatonin Demonstrates Anti-Aging Effects in Human Skin
Topical melatonin improves hydration and firmness and reduces wrinkle depth and surface roughness in clinical studies
AAD: AI-Based Medical Device Has High Accuracy for Skin Cancer
Sensitivity of DERM+ for identifying melanoma was 93.7 percent and for SCC, BCC was 100 and 99.2 percent
No Link Found Between Childhood Atopic Dermatitis and Markers of Cardiovascular Risk
Authors say universal screening of all children with atopic dermatitis is unlikely to improve identification of early cardiovascular risk
Patients With Psoriasis Have Elevated Risk for Complications After Total Hip Arthroplasty
Higher superficial SSI, deep SSI, wound complications, sepsis, aseptic revision reported for those with cutaneous psoriasis
AAD: Significant Benefits Seen for Brepocitinib 30 mg in Dermatomyositis
Mean Total Improvement Score significantly improved at week 52; brepocitinib was superior for all nine secondary outcomes
24 of 1268